This case study highlights how Labcorp Drug Development helped multiple sponsors run their pivotal studies to develop a first-in-class drug in Japan. This was made possible by programmatic model approach leading to completing the study in time and budget.

Supply chain disruptions and manufacturing shortages have significantly affected the clinical trial industry, an issue exacerbated by an unprecedented demand for clinical trial kits.

Labcorp was approached by a client who wants to establish European Food Safety (EFSA) Approved import tolerances for a crop protection product (CPP) not registered in Europe and widely used on bananas.

Labcorp was approached by a client who, as part of a regulatory submission, needed to create a laboratory-scale test setup for conducting post-harvest fumigation studies of multiple commodities at different controlled temperatures.

The Extended One Generation Reproductive Toxicity Study (EOGRTS, EU B.56, OECD TG 443) has been the information requirement for reproductive toxicity under the Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH, Annexes IX and X, Section 8.7.3.) since March 2015.

This case study outlines how the team supported the sponsor's needs - and handled unexpected volume surges - to meet regulatory compliance and serve as more than a partner.

A startup company (with the help of two innovative physicians) developed a tool that provides a safer, more effective way to alleviate a common orthopedic condition. Although early funding came at a cadence that kept progress moving steadily ahead, rounds for managing the entire life cycle to reach commercial distribution were relatively small.

At Labcorp, we strive to be more than just a partner. Our robust knowledge of mobile healthcare includes over 10 years of experience in providing in-home services, site support and central pharmacy solutions that are solely dedicated to the support of clinical trials.